HXP-GPOVac ,AZD1222

2 trials

Sponsors

The Government Pharmaceutical Organization

Conditions

Healthy male and female subjects Healthy male and female subjects

Phase 3

Phase 3 study, to evaluate the safety and immunogenicity of HXP-GPOVac vaccine in comparison to AstraZeneca's AZD1222 COVID-19 vaccine

Active, not recruitingTCTR20220120002

The Government Pharmaceutical OrganizationHealthy male and female subjects Healthy male and female subjects

Start: 2022-01-27Target: 4000Updated: 2026-03-30

Phase 3 study, to evaluate the safety and immunogenicity of 10 mcg HXP-GPOVac COVID-19 vaccine boost in comparison to a viral vector-based COVID-19 vaccines

TCTR20221026004

The Government Pharmaceutical OrganizationHealthy male and female subjects Healthy male and female subjects

Start: 2022-12-23Target: 4000Updated: 2026-03-30